תפריט נגישות
ניגודיות עדינהניגודיות גבוהה
מונוכרום
הדגשת קישורים
חסימת אנימציה
פונט קריא
סגור
איפוס הגדרות נגישות
להורדת מודול נגישות חינם תפריט נגישותניגודיות עדינהניגודיות גבוההמונוכרוםהדגשת קישוריםחסימת אנימציהפונט קריאסגוראיפוס הגדרות נגישותלהורדת מודול נגישות חינםSoad Haj Yahia
Diti Machnes-Maayan
Shirly Frizinsky
Ramit Maoz-Segal
Irena Offenganden
Ron S Kenett
Nancy Agmon-Levin
Ran Hovav
Mona I Kidon
Background: Between 25%-30% of peanut allergic (PA) children, have a relatively high threshold peanut allergy (HTPA), with a single maximal tolerated dose (SMTD) higher than 100 mg of peanut protein (PP). However, this threshold may decrease with time, age, exercise, illness, sleep deprivation, and other covariates.
Objective: To explore the feasibility of a simplified oral immunotherapy (OIT) protocol, in a group of children with HTPA.
Methods: PA children with an SMTD higher than 100mg, were placed on a 40 week OIT protocol of either 300 mg/day of PP or 100 mg/day for 20 weeks followed by 300 mg/day for 20 weeks. A repeat open peanut food challenge was performed after 40 weeks of treatment and at a 6 months follow-up visit. After the 40 week challenge, all children received a maintenance dose of 2gr PP 3 times a week.
Results: 28 children with HTPA were enrolled, 56% boys, 89% younger than 6yo, with a mean SMTD of 304 mg (95% CI 229-378). All were placed on the OIT protocol described above. Two children were not compliant and 3 had allergic reactions at home on the dose previously tolerated in clinic, 23 completed the 40 week protocol, All were able to consume 2 gr of PP. The mean tolerated dose at the 6 months follow-up, was 8gr. This enabled most children age appropriate dietary inclusion of peanut containing products.
Conclusion: In children with high threshold PA, a simple, fixed dose OIT can be both safe and efficacious.
Soad Haj Yahia
Diti Machnes-Maayan
Shirly Frizinsky
Ramit Maoz-Segal
Irena Offenganden
Ron S Kenett
Nancy Agmon-Levin
Ran Hovav
Mona I Kidon
Background: Between 25%-30% of peanut allergic (PA) children, have a relatively high threshold peanut allergy (HTPA), with a single maximal tolerated dose (SMTD) higher than 100 mg of peanut protein (PP). However, this threshold may decrease with time, age, exercise, illness, sleep deprivation, and other covariates.
Objective: To explore the feasibility of a simplified oral immunotherapy (OIT) protocol, in a group of children with HTPA.
Methods: PA children with an SMTD higher than 100mg, were placed on a 40 week OIT protocol of either 300 mg/day of PP or 100 mg/day for 20 weeks followed by 300 mg/day for 20 weeks. A repeat open peanut food challenge was performed after 40 weeks of treatment and at a 6 months follow-up visit. After the 40 week challenge, all children received a maintenance dose of 2gr PP 3 times a week.
Results: 28 children with HTPA were enrolled, 56% boys, 89% younger than 6yo, with a mean SMTD of 304 mg (95% CI 229-378). All were placed on the OIT protocol described above. Two children were not compliant and 3 had allergic reactions at home on the dose previously tolerated in clinic, 23 completed the 40 week protocol, All were able to consume 2 gr of PP. The mean tolerated dose at the 6 months follow-up, was 8gr. This enabled most children age appropriate dietary inclusion of peanut containing products.
Conclusion: In children with high threshold PA, a simple, fixed dose OIT can be both safe and efficacious.
